WBP2 Inhibitors
Chemical inhibitors of WBP2 employ various molecular mechanisms to impede its function within cellular pathways. Palbociclib, a CDK4/6 inhibitor, interferes with the cell cycle by preventing the phosphorylation of proteins that interact with WBP2, which is essential for its role in cell cycle progression. Similarly, Trichostatin A, a histone deacetylase inhibitor, disrupts WBP2's ability to coactivate transcription by altering the acetylation state of histones at the genomic locations of WBP2 target genes. LY294002, a PI3K inhibitor, can inhibit WBP2 by obstructing the PI3K/AKT pathway, leading to diminished transcriptional activity due to reduced activation of essential downstream targets. U0126 and SB203580, which inhibit MEK1/2 and p38 MAPK respectively, thwart the MAPK/ERK and p38 MAPK pathways, crucial for WBP2's coactivation function in transcriptional regulation.
In addition to these, Rapamycin, an mTOR inhibitor, suppresses WBP2 activity by inhibiting mTORC1 signaling, which plays a part in controlling the transcriptional coactivation capabilities of WBP2. Y-27632, a ROCK inhibitor, impacts WBP2 by preventing the phosphorylation of substrates that are key to the organization of the cytoskeleton and may influence WBP2's role in cellular processes. SP600125, a JNK pathway inhibitor, and ICG-001, a Wnt/β-catenin pathway inhibitor, both disrupt pathways that regulate transcription factors and coactivators, including WBP2. Furthermore, PF-562271, a FAK/Pyk2 inhibitor, could influence WBP2 activity by altering cellular adhesion and motility. XAV-939 and AZD8055, which are tankyrase and mTOR kinase inhibitors respectively, destabilize cellular signaling pathways crucial for WBP2's coactivation function, with XAV-939 promoting β-catenin degradation and AZD8055 blocking both mTORC1 and mTORC2 pathways.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor that can inhibit WBP2 by preventing the phosphorylation of proteins that WBP2 interacts with, leading to a halt in cell cycle progression and WBP2-mediated transcriptional activity. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, a histone deacetylase inhibitor, can inhibit WBP2 by altering the acetylation state of histones associated with WBP2 target genes, thereby inhibiting the transcriptional coactivation ability of WBP2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, can inhibit WBP2 by blocking the PI3K/AKT pathway, leading to reduced transcriptional activity of WBP2 due to decreased activation of downstream targets necessary for WBP2's coactivator functions. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126, an inhibitor of MEK1/2, can inhibit WBP2 by preventing the activation of the MAPK/ERK pathway, which is necessary for the transcriptional coactivation function of WBP2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAPK inhibitor, can inhibit WBP2 by blocking the p38 MAPK pathway, which may be required for the full transcriptional coactivation capability of WBP2. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, can inhibit WBP2 by blocking mTORC1 signaling, which may be involved in the regulation of WBP2's activity as a transcriptional coactivator. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632, a ROCK inhibitor, can inhibit WBP2 by preventing the phosphorylation of substrates involved in cytoskeleton organization, potentially affecting cellular processes where WBP2 functions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, an inhibitor of JNK, can inhibit WBP2 by blocking the JNK signaling pathway, which may be involved in the regulation of transcription factors and coactivators, including WBP2. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
XAV-939, a tankyrase inhibitor, can inhibit WBP2 by stabilizing Axin and promoting β-catenin degradation, thereby reducing the transcriptional coactivation potential of WBP2 in the Wnt pathway. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055, an mTOR kinase inhibitor, can inhibit WBP2 by blocking both mTORC1 and mTORC2 pathways, potentially disrupting the signaling required for WBP2's coactivation function in growth and proliferation. | ||||||